Immix Biopharma, Inc. (IMMX) vs Lexicon Pharmaceuticals, Inc. (LXRX)
Immix Biopharma, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Immix Biopharma, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($854.3M and $844.3M). Immix Biopharma, Inc. has the higher net margin (0.00% vs −147.4%) and the higher return on invested capital (0.00% vs −96.4%). Across the 13 metrics below, Immix Biopharma, Inc. leads on 10 and Lexicon Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | IMMX | LXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 99.14% | 65.16% |
| Operating margin | 0.00% | (131.43%) | 0.00% |
| Net margin | 0.00% | (147.38%) | 0.00% |
| Free cash flow margin | 0.00% | (156.71%) | 0.00% |
| Return on equity | (34.18%) | (40.21%) | (57.72%) |
| Return on assets | (31.34%) | (25.70%) | (49.22%) |
| Return on invested capital | 0.00% | (96.36%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack